Q-omics provides the consensus-scored CDH24 profile across patient tissues and cancer cell-line models. CDH24 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CDH24 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, CDH24 RNA expression shows 18,644 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where CDH24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH24 survival associations across molecular data types. CDH24 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH24 RNA expression–survival associations across cancer types. High CDH24 expression shows unfavorable associations in UVM, MESO, ACC, LUAD, LIHC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CDH24 RNA expression.
This table summarizes CDH24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CDH24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH24 shows higher tumor expression in HNSC, KIRP, COAD, BLCA, LUAD and LIHC. The HNSC box plot shows higher CDH24 RNA expression in tumor versus normal tissue (log2 FC = +1.703, t-test p < 0.001).
This table shows molecular features associated with CDH24 in patient tissues and cancer cell lines. In patient samples, CDH24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
